Get In Touch

Global Bone and Mineral Metabolism Disorders Treatment Market: Snapshot

The global bone and mineral metabolism disorders treatment market is prognosticated to secure a rising growth with the surging occurrence of metabolic disorders and chronic kidney diseases (CDKs). It is approximated that millions of Americans above the age of 50 years are suffering from osteoporosis while a closer count of the people could be at the risk of developing the bone disease. This could promote promising opportunities in the U.S. market for bone and mineral metabolism disorders treatment. Furthermore, a surging awareness about the management of such disorders among healthcare professionals and improved access to diagnosis are prophesied to unveil new avenues in the market. On the whole, the market is envisioned to showcase a steady growth during the forecast period.

The demand in the global bone and mineral metabolism disorders treatment market could be further strengthened by changes encouraged to cut down treatment costs. This is anticipated to be on account of the intensified competition between local and international companies. The dynamics of the market are expected to undergo favorable changes, owing to the availability of an expansive gamut of products in different strengths and forms. North America and Europe could be lucrative markets for bone and mineral metabolism disorders treatment in view of their potential to bear higher product costs. Asia Pacific, on the other hand, is projected to make its contribution to the global market while riding on the elevating incidences of metabolic diseases and stenting in children and profitable population dynamics.

Bone and mineral metabolism disorder is a collective term used to describe various conditions that make bones weak. Bone mineral metabolism maintains sufficient concentration of inorganic ions in blood serum. Progressive chronic kidney disease, especially end-stage renal disease (ESRD), is responsible for adverse changes in bone and mineral metabolism. Increase in serum parathyroid hormone levels due to fall in glomerular filtration rate is an indicator of bone disorder caused by chronic kidney disease. Reduction in kidney function leads to changes in bone mineral homeostasis and in levels of parathyroid hormone (PTH), 25-hydroxyvitamin D, 1,25-dihydroxyvitamin D, and fibroblast growth factor-23 (FGF-23). Disorders of mineral metabolism in chronic kidney disease (CKD) have been associated with higher mortality than anemia and inadequate dialysis. Increased prevalence of chronic kidney diseases, rising geriatric population, and changing lifestyles which lead to mineral and hormonal disturbances drive the bone and mineral metabolism disorders treatment market. However, high cost of the treatment and side effects of the medications hamper market growth.

The bone and mineral metabolism disorders treatment market can be segmented based on type of disorder, type of medication used to prevent and treat bone and mineral disorders, and region. In terms of type of disorder, the market can be classified into osteoporosis, osteomalacia, rickets, osteitis fibrosa cystica, adynamic bone disease, vascular calcification, and Pagets disease. Osteoporosis and vascular calcification are highly prevalent among the CKD population and are progressing rapidly. Medications are segmented based on type of disorder to be treated. For instance, treatment of osteoporosis involves prevention of fractures. Hence, the osteoporosis medications segment can be classified into drugs and nutrients used for primary prevention of fractures including calcium and vitamin D supplements, and hip protectors and hip pads to avoid hip damage due to fall. Drugs utilized to treat osteoporosis are categorized into antiresorptive drugs (to reduce bone loss) and anabolic agents (to build bone). Major chemical classes under antiresorptive drugs are bisphosphonates, estrogen, selective estrogen receptor modulators (SERMs), biological, and calcitonin. In 2010, the FDA approved monoclonal antibody named Denosumab for the treatment of postmenopausal women who are at high risk of fractures. Teriparatide is a synthetic form of parathyroid hormone and is the only FDA-approved anabolic. Phosphate binding agents and dialysis are used in the treatment of hyperphosphatemia. There are three types of phosphate binders: calcium based binders, non-calcium based binders, non-metal based binders, and metal-based binders. Aluminum and magnesium-based binders. Vitamin D analog is indicated in the management of hypocalcemia in patients undergoing chronic renal dialysis. Management of secondary hyperparathyroidism in patients not yet on dialysis is done with calcitriol capsules and oral solution. Calcimimetic agent (cinacalcet) is indicated for the treatment of secondary hyperparathyroidism in patients with CKD on dialysis and for the treatment of hypercalcemia in patients with parathyroid carcinoma. Apart from these disease specific agents, pain managing medications and several types of surgeries are driving the market.

In terms of region, the bone and mineral metabolism disorders treatment market can be segmented into North America, Latin America, Europe, Asia Pacific, and Middle East & Africa. North America is leading the global market. Several collaborative efforts taken by major companies to enhance their research outcomes in this area, world-class diagnosis facilities, increased awareness about disorders, rising geriatric population, and growing obese population are drivers of the bone and mineral metabolism disorder treatment market in North America. Europe is witnessing strong growth due to increasing geriatric population and higher incidence of disorders in postmenopausal women. Moreover, the market in Asia Pacific is expected to witness significant growth during the forecast period due to increasing incidence of the disorder, negligence of diet and lack of nutrition, and introduction of advanced diagnosis technologies.

Key players operating in the bone and mineral metabolism disorder treatment market are Eli Lilly and Company, F. Hoffmann-La Roche, Pfizer, Inc., Actavis plc, Teva Pharmaceutical Industries Ltd., Novo Nordisk A/S, Amgen, Inc., Merck & Co., Inc., and Novartis International AG.

This study by TMR is all-encompassing framework of the dynamics of the market. It mainly comprises critical assessment of consumers' or customers' journeys, current and emerging avenues, and strategic framework to enable CXOs take effective decisions.

Our key underpinning is the 4-Quadrant Framework EIRS that offers detailed visualization of four elements:

  • Customer Experience Maps
  • Insights and Tools based on data-driven research
  • Actionable Results to meet all the business priorities
  • Strategic Frameworks to boost the growth journey

The study strives to evaluate the current and future growth prospects, untapped avenues, factors shaping their revenue potential, and demand and consumption patterns in the global market by breaking it into region-wise assessment.

The following regional segments are covered comprehensively:

  • North America
  • Asia Pacific
  • Europe
  • Latin America
  • The Middle East and Africa

The EIRS quadrant framework in the report sums up our wide spectrum of data-driven research and advisory for CXOs to help them make better decisions for their businesses and stay as leaders.

Below is a snapshot of these quadrants.

1. Customer Experience Map

The study offers an in-depth assessment of various customers’ journeys pertinent to the market and its segments. It offers various customer impressions about the products and service use. The analysis takes a closer look at their pain points and fears across various customer touchpoints. The consultation and business intelligence solutions will help interested stakeholders, including CXOs, define customer experience maps tailored to their needs. This will help them aim at boosting customer engagement with their brands.

2. Insights and Tools

The various insights in the study are based on elaborate cycles of primary and secondary research the analysts engage with during the course of research. The analysts and expert advisors at TMR adopt industry-wide, quantitative customer insights tools and market projection methodologies to arrive at results, which makes them reliable. The study not just offers estimations and projections, but also an uncluttered evaluation of these figures on the market dynamics. These insights merge data-driven research framework with qualitative consultations for business owners, CXOs, policy makers, and investors. The insights will also help their customers overcome their fears.

3. Actionable Results

The findings presented in this study by TMR are an indispensable guide for meeting all business priorities, including mission-critical ones. The results when implemented have shown tangible benefits to business stakeholders and industry entities to boost their performance. The results are tailored to fit the individual strategic framework. The study also illustrates some of the recent case studies on solving various problems by companies they faced in their consolidation journey.

4. Strategic Frameworks

The study equips businesses and anyone interested in the market to frame broad strategic frameworks. This has become more important than ever, given the current uncertainty due to COVID-19. The study deliberates on consultations to overcome various such past disruptions and foresees new ones to boost the preparedness. The frameworks help businesses plan their strategic alignments for recovery from such disruptive trends. Further, analysts at TMR helps you break down the complex scenario and bring resiliency in uncertain times.

The report sheds light on various aspects and answers pertinent questions on the market. Some of the important ones are:

1. What can be the best investment choices for venturing into new product and service lines?

2. What value propositions should businesses aim at while making new research and development funding?

3. Which regulations will be most helpful for stakeholders to boost their supply chain network?

4. Which regions might see the demand maturing in certain segments in near future?

5. What are the some of the best cost optimization strategies with vendors that some well-entrenched players have gained success with?

6. Which are the key perspectives that the C-suite are leveraging to move businesses to new growth trajectory?

7. Which government regulations might challenge the status of key regional markets?

8. How will the emerging political and economic scenario affect opportunities in key growth areas?

9. What are some of the value-grab opportunities in various segments?

10. What will be the barrier to entry for new players in the market?

Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.

Custom Market Research Services

TMR offers custom market research services that help clients to get information on their business scenario required where syndicated solutions are not enough.


Bone Mineral Metabolism Disorders Treatment Market